- Home
- SYBX vs NERV Comparison
SYBX vs NERV Comparison
Compare SYBX & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYBX
- NERV
- Stock Information
- Founded
- SYBX N/A
- NERV 2007
- Country
- SYBX United States
- NERV United States
- Employees
- SYBX N/A
- NERV N/A
- Industry
- SYBX Biotechnology: Pharmaceutical Preparations
- NERV Biotechnology: Pharmaceutical Preparations
- Sector
- SYBX Health Care
- NERV Health Care
- Exchange
- SYBX Nasdaq
- NERV Nasdaq
- Market Cap
- SYBX 16.5M
- NERV 16.0M
- IPO Year
- SYBX N/A
- NERV 2014
- Fundamental
- Price
- SYBX $1.43
- NERV $2.11
- Analyst Decision
- SYBX Hold
- NERV Hold
- Analyst Count
- SYBX 3
- NERV 1
- Target Price
- SYBX $1.00
- NERV $5.00
- AVG Volume (30 Days)
- SYBX 24.4K
- NERV 36.3K
- Earning Date
- SYBX 03-18-2025
- NERV 02-20-2025
- Dividend Yield
- SYBX N/A
- NERV N/A
- EPS Growth
- SYBX N/A
- NERV N/A
- EPS
- SYBX N/A
- NERV N/A
- Revenue
- SYBX $2,777,000.00
- NERV N/A
- Revenue This Year
- SYBX N/A
- NERV N/A
- Revenue Next Year
- SYBX N/A
- NERV N/A
- P/E Ratio
- SYBX N/A
- NERV N/A
- Revenue Growth
- SYBX 292.23
- NERV N/A
- 52 Week Low
- SYBX $1.22
- NERV $2.03
- 52 Week High
- SYBX $3.73
- NERV $13.49
- Technical
- Relative Strength Index (RSI)
- SYBX 49.27
- NERV 42.63
- Support Level
- SYBX $1.36
- NERV $2.10
- Resistance Level
- SYBX $1.47
- NERV $2.39
- Average True Range (ATR)
- SYBX 0.08
- NERV 0.12
- MACD
- SYBX 0.00
- NERV -0.01
- Stochastic Oscillator
- SYBX 43.75
- NERV 21.62
About SYBX Synlogic Inc.
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.